Research
Weekly weight-loss injection combo shows promise
The Brief
- Two lower doses of CagriSema, a weekly injection combining cagrilintide and semaglutide, led to substantial weight loss in the trial.
- The trial enrolled adults with obesity, or with overweight plus a weight-related health condition such as high blood pressure or sleep apnea.
Why it matters
The results add evidence that a weekly combination of two appetite-reducing medicines can produce substantial weight loss, which matters for readers following obesity treatment research.
Who’s affected
- clinicians and researchers in obesity treatment
- adults with obesity or overweight and weight-related health conditions
Two lower doses of CagriSema, a weekly injection combining two appetite-reducing medicines, cagrilintide and semaglutide, led to substantial weight loss in adults with obesity or with overweight and a weight-related health condition such as high blood pressure or sleep apnea…